Sensorium Therapeutics Inc. has reported that the U.S. FDA has cleared the IND application for SNTX-2643 (SENS-01), its lead anxiety program. First-in-human dosing begins in Q3 2025.
Work at Sensorium Therapeutics Inc. has led to the identification of new serotonin transporter (SERT) inhibitors reported to be useful for the treatment of depression, anxiety and stress disorders.
Sensorium Therapeutics Inc. has identified mesembrine analogues acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of neurological disorders.
Sensorium Therapeutics Inc. has synthesized mesembrine derivatives acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
Sensorium Therapeutics Inc. has identified alkylated derivatives of mesembrine or mesembrenone acting as serotonin transporter (SERT) and/or phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
Research at Sensorium Therapeutics Inc. has led to the identification of deuterated alkaloids acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, depression, rheumatoid arthritis, stress and anxiety disorders.
Sensorium Therapeutics Inc. closed a $30 million series A round to fund the discovery and development of new psychiatric drugs, inspired by human ethnobotanical practices that date back hundreds or even thousands of years.
